Undifferentiated arthritis: Predictive factors of persistent arthritis and treatment decisions

Caspian Journal of Internal Medicine

Volumn 1, Issue 3, 2010, Pages 79-88

  Heidari, Behzad ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Predictive factor; Rheumatoid arthritis; Treatment; Undifferentiated arthritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STEROID;

ADJUVANT THERAPY; ANKLE EDEMA; ARTHRITIS; ARTICLE; BONE EROSION; BONE RADIOGRAPHY; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MORNING STIFFNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; SYNOVITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME;

EID: 84865310320     PISSN: 20086164     EISSN: 20086172     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Nell VP, Machold KP, Ebrel G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004; 43: 906-14.
2. Fleischmann RM. Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier. Clin Ther 1999; 21: 1429-42; discussion 1427-8.
3. Ikeda K, Cox S, Emery P. Aspects of early arthritis. Biological therapy in early arthritis-overtreatment or the way to go? Arthritis Res Ther 2007; 9: 211.
4. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Practice & Research Clin Rheumatol 2006; 20: 849-63.
5. Ma MH, Scott IC, Kingsley GH, Scott DL. Remission in early rheumatoid arthritis. J Rheumatol 2010; 37: 1444-53.
6. Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate mnotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69: 1298-304.
7. Finckh A, Bansback N, Marra CA, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009; 151: 612-21.
8. Farragher TM, Lunt M, Fu B, Bunn D, Symmons DP.Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis. Ann Rheum Dis 2010; 69: 689-95.
9. Durez P, Malghem J, Nzeusseu Toukap A, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007; 56: 3919-27.
10. Emery P, Salmon M. Early rheumatoid arthritis:time to aim for remission?.Ann Rheum Dis 1995; 54: 944-7.
11. Raissouni N, Gossec L, Ayral X, Dougados M. New concepts in the diagnosis and treatment of recent onset polyarthritis. Joint Bone Spine 2005; 72: 119-23.
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
13. Vvan der Heide A, Van der Heide A, Hofman DM, Jacobs JW, Bijlsma JW.Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995; 38: 1466-74.
14. Wollenhaupt J, Zeidler H. Undifferentiated arthritis and reactive arthritis. Curr Opin Rheumatol 1998; 10: 306-13.
15. Thabet MM, Huizinga TW, Van Der Heijde DM, van der Helm-van Mil AH. The prognostic value of baseline erosions in undifferentiated arthritis. Arthritis Res Ther. 2009; 11: R155.
16. Van Der Helm- Van Mil AH, Detert J, I, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008; 58: 2241-7.
17. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symettncal synovitis in an early arthritis clinic.Br J Rheumatol 1993; 32: 97-103.
18. Harrison B, ymmons D. Early inflammatory polyarthritis: results from the Norfalk Arthritis Register with a review of literature. 11. OutcoMe at three years.Rheumatology 2000; 39:939-49.
19. Hüllsemann JL, Zeidler H. Undifferentiated arthritis in an early synovitis out-patient chic. Clin Exp Rheumatol. 1995; 13: 37-43.
20. Inaoui R, Bertin P, Preux PM, Treves R. Outcome of patients with undifferentiated chronic monoarthritis: retrospective study of 46 cases. Joint Bone pine. 2004;71:209-13.
21. Mau W, Raspe HH, Mersjann H. Early arthritides: nosography, nosology, and diagnostic criteria. c and J Rheumatol uppl 1989; 79: 3-12.
22. Sampaio-Barros PD, Bortoluzzo AB, Conde RA, et al. Bértolo MB. Undifferentiated spondyloarthritis: a longterm followup. J Rheumatol 2010; 37: 1195-9.
23. Kumar A, Bansal M, Snvastava DN, et al. Long-term outcome of undifferentiated spondylarthropathy. Rheumatol Int 2001; 20: 221-4.
24. van Gaalen FA, Lmn-Rasker P, van Venrooij WJ, et al. Autoantibodies to cyclic citrullmated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-15.
25. Machold KP, Nell VP, Stamm TA, et al. The Austrian Early Arthritis Registry. Clin Exp Rheumatol 2003; 21: S113-7.
26. Glennås A, Kvien TK, Andrup O, Karstensen B, Munthe E.Recent onset arthritis in the elderly: a 5 year longitudinal observational study. J Rheumatol 2000; 27: 101-8.
27. Morel J, Legouffe MC, Bozonat MC, et al. Outcomes in patients with incipient undifferentiated arthritis. Joint Bone pine 2000; 67: 49-53.
28. Kim TH, Lee H, Ji JD, et al. Undifferentiated spondyloarthropathy in Korea: focusing on peripheral arthritis. J Korean Med Sci 2002; 17: 71-4.
29. Green M, Marzo-Ortega H, McGonnalge D, et al. Persistence of mild&, early inflammatory arthritis: the imporance of disease duration ,rheumatoid factor ,and the shared epitope. Arthritis Rheum 1999; 42: 2184-8.
30. Tamai M, Kawakami A, Uetam M, et al. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. Arthritis Rheum 2009; 15: 61: 772-8.
31. Mjaavatten MD, Uhhg T, Haugen AJ, et al. Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort. Arthritis Res Ther 2009; 11: R146.
32. Visser H, Ie Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis Arthritis Rheum 2002; 46: 357-65.
33. Symmons DP, ilman AJ. Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register. Arthritis Res Ther 2006; 8: 214.
34. Heidari B, Firouzjahi A, Heidan P, Hajian K. The prevalence and diagnostic performance of anti-cyclic citrullmated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis. Ann Saudi Med 2009; 29: 467-70.
35. Mjaavatten MD, Van der Heijde D, Uhlig T, et al. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis. Arthritis Res Ther 2010; 12: R76.
36. Raza K, Breese M, Nightingale P et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis J Rheumatol 2002;32:231-8.
37. El Miedany Y, Youssef S, Mehanna AN, El Gaafary M. Development of a scoring system for assessment of outcome of early undifferentiated inflammatory synovitis. Joint Bone pine 2008; 75: 155-62.
38. Brown AK, Quinn MA, Kanm Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease modifying anti-rheumatic drug-induced clinical remission: Evidence from an imaging study may explain structural progression. Arthritis Rheum 2010; 54; 3761-73.
39. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2010; 16: [Epub ahead of print
40. Verpoort KN, van Dongen H, Allaart CF, et al. Undifferentiated arthritis-disease course assessed in several inception cohorts. Clin Exp Rheumatol 2004; 22: 35: S12-7.
41. Eguchi K [Early prediction of joint destruction in rheumatoid arthritis]. Clin Calcium 2007; 17: 517-25
42. van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56: 433-40.
43. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808.
44. Jansen AL, van der Horst-Bruinsma I, van chaardenburg D, et al. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002; 29: 2074-6.
45. Quinn MA, Green MJ, Marzo-Ortega H, et al. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum 2003; 48: 3039-45.
46. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma IE, Dijkmans BA. One year outcome of undifferentiated polyarthritis. Ann Rheum Dis 2002; 6: 700-3.
47. Machold KP, tam MTA, Eberl GJ, et al. Very recent onset arthritis-clinical Jaboratory and radiological findings during the first year of disease.J Rheumatol 2002; 29: 2278-87.
48. Karelia K, Tiitinen S, Luukkainen R. Long-term prognosis of monoarthritis. A follow-up study. Scand J Rheumatol 1983; 12: 374-6.
49. Heidari B, Heidan P, Tayebi ME. The value of changes in CRP and ER for predicting treatment response in rheumatoid arthritis. APLAR J of Rheumatol 2007; 10: 23-8.
50. Heidari B, Lotfi Z, Firouzjahi AR, Heidan P. Comparing the diagnostic value of anti-cyclic citrullmatied peptid antibody and rheumatoid factor for rheumatoid arthntis. Research in medicine. 2009; 33: 156-161.
51. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63.
52. van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis. Ann N Y Acad ci 2008; 1143: 268-85.
53. Heidari B, Abedi H, Firouzjahi A, Heidan P. Diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody for rheumatoid arthritis. Rheumatol Int 2009; [Epub ahead of print]
54. Heidari B, Hajian K, Firouzjahi A. Correlation between serum CRP levels and disease activity in Rheumatoid arthntis Kowsar Medical Journal 2004; 9: 20-8.
55. Devauchelle-Pensec V, Saraux A, Alapetite S, Colin D, Le Goff P. Diagnostic value of radiographs of the hands and feet in early rheumatoid arthritis. Joint Bone Spine 2002; 69: 434-41.
56. Rahmani M, Chegim H, Najafizadeh R, et al. Detection of bone erosion in early rheumatoid arthritis: ultrasonography and conventional radiography versus non-contrast magnetic resonance imaging. Clin Rheumatol 2010; 29: 883-91. Epub 2010 Mar 19.
57. Tamai M, Kawakami A, Uetam M, et al. A prediction rule for disease outcome in patients with undifferentiated arthritis using magnetic resonance imaging of the wrists and finger joints and serologic autoantibodies. Arthritis Rheum 2009; 15; 61:772-8.
58. van Aken J, van Dongen H, le Cessie S, et al. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis 2006; 65:20-5. Epub 2005 May 18.
59. Heidari B, Jalah F. Bone densitometry in patients with rheumatoid arthritis. Acta Medica Iramca. 2005; 43: 99-104.
60. Cush JJ. Early rheumatoid arthritis - is there a window of opportunity? J Rheumatol uppl 2007; 80:1-7.
61. Köller M, Nobauer-Huhmann I. Early arthritis: action desired - treatment required.] Wien Med Wochenschr 2009; 159 (3-4): 66-9.
62. Villa-Bianco JI, Calvo-Alen J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging 2009; 26: 739-50.
63. Dougados M, Com be B, Cantagrel A, et al. ET AL. Combination therapy in early rheumatoid arthritis:a randomized, controlled double blind, 52 weeks clinical trial of sulfasalazine and methtrexate compared with the single components. Ann Rheum Dis 1999; 58: 220-5.
64. Hider L, ilman AJ, Thomson W, et al. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis 2009; 68 (1):57-62. Epub 2008 Feb 21.
65. Heidari B, Byam K, Hajian KA study of the efficacy and toxicity of long-term methotrexate therapy in rheumatoid arthritis. Journal of hahid adoghi University. 2003; 10: 56-62.
66. van Dongen H, van Aken J, Lard LR, Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56: 1424-32.
67. Raza K, Filer A. Predicting the development of RA in patients with early undifferentiated arthritis. Best Pract Res Clin Rheumaol 2009; 23: 25-36.
68. Boer M, Verhoeven AC, Markuse HM, et al. Randomised comparison of combined step-down prednisolone methtrexate and sulfasalzine with sulfasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
69. Ibañez M, Ortiz AM, Castrejon I, et al. A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. Arthritis Res Ther 2010; 12: R50. Epub 2010 Mar 23.
70. Todoerti M, Scire CA, Boffim N, et al. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci 2010; 1193: 139-45.
71. Van Everdmgen AA, Jacobe JW, eiwertsz Van Reesema DR, Bijlsma JWJ. Low dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease modifying properties and side effects: a randomized double blined, placebo controlled clinical trial. Ann Intern Med 2002; 136: 1-12.